Fecal Microbiota Transplantation in the Treatment of Major LARS

ConditionsLow Anterior Resection Syndrome Fecal Microbiota Transplantation

Trial statusNot yet recruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age18-80

SponsorPeking University People's Hospital

About this trial

Randomized trial to assess FMT efficacy in improving bowel function for major LARS patients. 40 subjects, blinded, randomized to FMT or probiotics. Pre-post 16S sequencing, 4-week follow-up for bowel symptoms, 8-week microbiota analysis.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

None

Disqualifiers

None

Trial design

Design model

Sequential

Treatments tested in this trial

fecal microbiota transplantation
Biological/Vaccine
During the treatment, a colonoscopic colonic catheter will be placed via the anus, with the experimental group receiving FMT solution matched to the patient's microbiota for intra-intestinal administration.
Formulated probiotic supplements
Dietary supplement
During the treatment, a colonoscopic colonic catheter will be placed via the anus, with the control group receiving a standardized probiotic formula.

Treatment groups

40 Participants

are divided into 2 treatment groups

Group A: Fecal flora transplantation groupExperimental treatment 1 intervention

Group B: Formulated probiotics groupActive comparator 1 intervention

Trial outcomes

Primary outcomes

bowel function

LARS score

Time frame

4 weeks and 8 weeks

Shannon index

biodiversity monitoring

Time frame

8 weeks

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Peking University People's Hospital

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: